EPRX

$EPRX chatter on StockTwits

• 
  John Heerdink@jheerdinkBullish17h

  $EPRX Dr. James Helliwell, Chief Executive Officer of Eupraxia, said, "What is especially encouraging in this finding is that EP-104GI is continuing to demonstrate consistent biological responses. Patients are seeing improvement in their ability to swallow without food becoming stuck, in the pain they experience with swallowing, in endoscopic findings of disease and histologic severity of disease. These improvements seem to be showing durability to 52 weeks. We continue to anticipate our key Phase 2b placebo-controlled interim readout in Q4 of this year." https://finance.yahoo.com/healthcare/articles/eupraxia-pharmaceuticals-reports-symptom-response-120000985.html

  View on StockTwits ↗
• 
  Quantumup@QuantumupJul 30

  Guggenheim⬇️ $PHAT to $22, reitd Buy/said PHAT has delivered robust Q/Q Voquezna TRx and revenue growth, exceeding consensus expectations, as well as achieving operational profitability for the first time in the company's history. $EPRX $BMY AZN - AMGN APGE - ABBV Here's what else Guggenheim had to say: https://x.com/Quantumup1/status/2082889761782370489?s=20

  View on StockTwits ↗
• 
  Urban@SkusekJul 23

  $EPRX 8-10$

  View on StockTwits ↗
• 
  Gary Reitz@Moneybags789BullishJul 22

  $EPRX still

  View on StockTwits ↗
• 
  John Heerdink@jheerdinkBullishJul 11

  $EPRX "We are delighted for Robert, Amy and Helen to join our Board of Directors at a pivotal stage for the company." said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. "Their collective expertise across late-stage drug development, commercial strategy, and global product launches will be invaluable as we execute on several key upcoming milestones for EP-104GI and continue to expand our pipeline. Their appointments reflect the commitment of Eupraxia to advancing and expanding our gastroenterology assets in an efficient and effective manner. I also want to thank Paul Geyer and Michael Wilmink for all of the support and contributions they have made to Eupraxia over the last decade as we proved the function and potential of the Diffusphere technology." https://finance.yahoo.com/healthcare/articles/eupraxia-pharmaceuticals-strengthens-board-three-120000733.html

  View on StockTwits ↗
• 
  John Heerdink@jheerdinkBullishJun 30

  $EPRX "Key Upcoming EoE Milestones" "For investors tracking catalysts, Eupraxia has already mapped out several important waypoints in EoE. The Phase 2b portion of RESOLVE—a randomized, placebo‑controlled study of EP‑104GI at a 120 mg total dose (20 injections of 6 mg)—is currently recruiting, with top‑line data expected in the third quarter of 2026, representing the next major inflection point for the program. Regulators in Australia and Canada have approved expansions to the RESOLVE protocol to explore higher doses, more injection sites, and longer follow‑up, with participant counts increasing and follow‑up durations extended to 52 weeks at higher doses, further enriching the dataset ahead of a potential registration trial. Taken together, these steps set up a 2026–2027 window...." https://vistapglobal.com/biologics-blister-bulls-eoe-and-yearly-shots-why-sanofi-and-eupraxia-belong-on-every-immunology-watchlist-eprx-regn-sny/

  View on StockTwits ↗
• 
  Gary Reitz@Moneybags789BullishJun 26

  $EPRX when the hell is the next catalyst for the stock, I haven’t heard news in months!

  View on StockTwits ↗
• 
  Brandon Matthew@bmatthewBullishJun 25

  $EPRX

  View on StockTwits ↗
• 
  Quantumup@QuantumupJun 25

  Oppenheimer🏁 $EPRX OP-$17 $PHAT $BMY AZN-AMGN APGE-ABBV Oppenheimer said—We initiate coverage of Eupraxia Pharmaceuticals with an Outperform rating and $17 PT, reflecting the differentiated potential for lead asset EP-104GI in eosinophilic esophagitis (EoE), an underappreciated indication dominated by burdensome steroids and high-cost biologics. By delivering sustained, localized fluticasone via a once-yearly endoscopic procedure, EP-104GI appears well-positioned to address a significant treatment gap where adherence remains critically challenging, supported by KOL feedback and prior Ph1b/2a data showing durable remission and promising safety. Ph2b interim data in 4Q26 is the next pivotal catalyst, where positive data, similar to Ph1b/2a, could unlock ~50% upside and support Ph3 initiation within current cash runway (~$140M into 2H28E). We forecast peak risk-adjusted EoE sales of $1.2B, following commercialization in 2031, and view Gl indication expansion as potential additional upside.

  View on StockTwits ↗
• 
  John Heerdink@jheerdinkBullishJun 22

  $EPRX https://vistapglobal.com/biologics-bulls-and-billion-dollar-plus-bets-abbvies-immunology-10-9b-durability-shopping-spree-explained-abbv-apge-eprx-regn-sny/

  View on StockTwits ↗
• 
  TeeWhy@TeeWhy1BullishMay 28

  $EPRX Keep climbing and releasing positive results and efficacy.

  View on StockTwits ↗
• 
  John Heerdink@jheerdinkBullishMay 21

  $EPRX $SNY $REGN EOE educational video https://youtu.be/hmRdI6kBAYI?si=XYUco_qvhWKwXJ6v

  View on StockTwits ↗
• 
  John Heerdink@jheerdinkMay 21

  $EPRX https://vistapglobal.com/stifel-places-target-on-eupraxia-a-once-yearly-esophagus-fix-in-a-world-of-weekly-shots-eprx-sny-regn-tak/

  View on StockTwits ↗
• 
  Quantumup@QuantumupMay 20

  Stifel🏁 $EPRX and said: We initiate coverage of Eupraxia Pharma (EPRX) with a Buy rating, $25 TP. $PHAT AZN - AMGN APGE $BMY Here's what else Stifel had to say in its initiation report: https://x.com/Quantumup1/status/2057195169074847811?s=20

  View on StockTwits ↗
• 
  John Heerdink@jheerdinkBullishMay 20

  $EPRX "Well-capitalized into H2 2028, beyond key catalysts with over $140 million cash". "The clinical data reported this quarter further reinforces the potential for EP-104GI to become an important new treatment for Eosinophilic Esophagitis (EoE),” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “With the capital from the recent financing, we are excited to continue development of EP-104GI in EoE and accelerate additional clinical programs in new indications within the GI field, where we believe that EP-104GI has the opportunity to work due to the Diffusphere’s ability to provide hyper-targeted delivery into diseased areas over a long period of time without the typical systemic exposure profile.” https://finance.yahoo.com/news/eupraxia-pharmaceuticals-reports-first-quarter-210000153.html

  View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.